Login to Your Account



Clinic Roundup


Wednesday, June 8, 2011
Nektar Therapeutics Inc., of San Francisco, reported single-dose Phase I interim data showing that NKTR-181 has an excellent safety and tolerability profile, with no dose-limiting tolerability issues observed to date. With slower entry into the central nervous system, the µ-opioid analgesic candidate has the potential to reduce the euphoria that underlies opioid abuse liability and dependence, as well as the side effects of respiratory depression and sedation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription